<DOC>
	<DOCNO>NCT01892371</DOCNO>
	<brief_summary>The goal Phase 1 part clinical research study find high tolerable dose AC220 ( quizartinib ) give either 5-azacitidine ( azacitidine ) cytarabine patient AML MDS . The goal Phase 2 part study learn quizartinib either azacitidine cytarabine help control AML MDS . The safety combination also study .</brief_summary>
	<brief_title>AC220 With 5-Aza Low Dose Cytarabine</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign receive quizartinib azacitidine cytarabine . Your doctor decide drug receive . You assign study phase base join study . Up 2 group 12 participant enrol Phase 1 portion study , 52 participant enrol Phase 2 . If enrolled Phase 1 portion , dose quizartinib cytarabine azacitidine receive depend join study . The first group participant receive low dose level quizartinib cytarabine azacitidine . Each new group receive high dose study drug group , intolerable side effect see . This continue high tolerable dose study drug find . If enrolled Phase 2 portion , receive quizartinib cytarabine azacitidine high dose tolerate Phase 1 portion . Study Drug Administration : Each study cycle 4 week long , may longer depend disease responds study drug . You take tablet form quizartinib mouth 1 time every day . You take time every day , empty stomach ( least 1 hour 2 hour meal morning ) . During first cycle , take Days 1-4 . If miss dose vomit dose , next dose increase make miss dose . You take next regular dose schedule time . If take azacitidine , receive vein 10-40 minute needle skin 1 time day Days 1-7 . The azacitidine dose give clinic . If take cytarabine , receive needle skin 2 time day Days 1-10 . You teach give cytarabine dos . Study Visits : On Day 1 Cycles 1 2 every 2-3 cycle end Month 6 , physical exam . One ( 1 ) time week Cycles 1-3 every 2-4 week end Month 6 , blood ( 1 teaspoon ) drawn routine test . On Day 28 Cycle 1 every 1-3 cycle end Month 6 , bone marrow aspiration check status disease On Days 1 , 5 , 8 , 12 Cycle 1 , Day 1 Cycles 2 3 , every 2-3 cycle end Month 6 , may 1 2 set EKGs . You may EKG time , depend time last quizartinib dose . You may additional EKGs , depend dose study drug receiving . After Month 6 , follow test procedure perform Day 1 cycle : - You physical exam . - Blood ( 1 teaspoon ) drawn routine test . - You EKG . Every 6-12 month Month 6 , often doctor think need , bone marrow aspiration check status disease . If study doctor think need , may extra clinic visit , test , procedure . Length Treatment : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , able follow study direction . This investigational study . Quizartinib FDA approve commercially available . It currently use research purpose . Cytarabine azacitidine FDA approve commercially available certain type MDS AML . The study drug combination investigational . Up 72 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . For Phase I Only : Refractory relapse disease define follow : Patients MDS CMML fail prior therapy ( e.g. , hypomethylating agent , clofarabine , and/or lenalidomide ) ; Patients AML fail prior induction therapy relapse prior therapy ; Patients ( age ) MDS CMML receive therapy hypomethylating agent progress AML eligible time diagnosis AML regardless prior therapy AML . The WHO classification use AML ; Patients eligible diagnosis receive prior therapy eligible candidate receive standard intensive therapy ( ie , highdose cytarabinebased chemotherapy ) . 2 . For Phase I Only : Patients eligible regardless FLT3 mutation status . 3 . For Phase I Only : Age &gt; /=18 year 4 . For Phase II Only : Patients MDS , CMML AML either : Age 60 year old newly diagnose , previously untreated . Prior therapy hydroxyurea single agent araC purpose control WBC acceptable . ; Age 18 year old refractory relapse disease receive one prior treatment regimen receive first salvage . For purpose , second induction cycle drug use first cycle , consolidation chemotherapy stem cell transplant CR ( CRp CRi ) consider part prior regimen . Prior therapy MDS ( malignancy ) consider prior regimen AML patient progress MDS ( malignancy ) . ; 5 . For Phase II : Patients ( age ) MDS CMML receive therapy hypomethylating agent progress AML eligible time diagnosis AML regardless prior therapy AML . The WHO classification use AML 6 . For Phase II : Patients must evidence FLT3 ITD recent assessment . 7 . For Phase I II : ECOG Performance Status &lt; /= 2 8 . For Phase I II : Adequate liver ( bilirubin &lt; /=2x ULN , ALT &lt; /=2.5x ULN ) renal ( creatinine &lt; /=2x ULN ) function . For patient suspect liver infiltration leukemia ALT &lt; /= 5 ULN . 9 . For Phase I II : Serum potassium , magnesium , calcium ( normalized albumin ) level least within institutional normal limit . 10 . For Phase I II : Patients must provide write informed consent . 11 . For Phase I II : Patients must chemotherapy 2 week prior enter study , unless evidence rapidly progressive disease , must recover toxic effect therapy least grade 1 . Use hydroxyurea patient rapidly proliferative disease allow start study therapy first four week therapy . The additional day Hydrea 28 permit clinically indicate , case case basis discussion PI . Other agent give transiently intention control rapid proliferation 12 dos single agent araC dose sorafenib also allow . 12 . For Phase I II : Women childbearing potential must practice contraception . Women consider childbearing potential include follow : menses least 2 year menses within 2 year amenorrheic least 2 month luteinizing hormone ( LH ) follicular stimulate hormone ( FSH ) value within normal range ( accord definition postmenopausal laboratory use ) bilateral oophorectomy radiation castration amenorrheic least 3 month . Females childbearing potential practice effective method contraception Effective method contraception include barrier method ( e.g. , condom , diaphragm ) , spermicidal jelly foam , oral , depo provera , injectable contraceptive , intrauterine device , tubal ligation , abstinence . Male patient female partner childbearing potential also practice contraception . 13 . For Phase I II : Negative urine serum pregnancy test . 1 . Patients know allergy hypersensitivity quizartinib , mannitol , AZA , cytarabine component . 2 . Patients electrolyte abnormality study entry define follow : Serum potassium &lt; 3.5 mEq/L despite supplementation , &gt; 5.5 mEq/L ; Serum magnesium institutional normal limit despite adequate management ; Serum calcium ( correct albumin level ) institutional normal limit despite adequate management . 3 . Patients know significant impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption quizartinib . 4 . Patients known disease concurrent severe and/or uncontrolled medical condition ( e.g . uncontrolled diabetes , cardiovascular disease include congestive heart failure , myocardial infarction within 6 month poorly control hypertension , chronic renal disease , active uncontrolled infection ) could compromise participation study . Patients current active malignancy remission &lt; 6 month , except patient carcinoma situ nonmelanoma skin cancer may active disease remission le 6 month . 5 . Patients know confirmed diagnosis HIV infection active viral hepatitis . 6 . Patients major surgical procedure within 14 day Day 1 . 7 . Patients know malignant disease central nervous system . 8 . Impaired cardiac function include follow : Screening ECG QTc &gt; 450 msec . The QTc interval calculate Fridericia 's correction factor ( QTcF ) Screening Day 5 prior first dose AC220 . The QTcF derive average QTcF triplicate . ; If QTcF &gt; 450 msec Day 5 , AC220 give ; Patients congenital long QT syndrome ; History presence sustain ventricular tachycardia require medical intervention ; Any history clinically significant ventricular fibrillation torsades de pointes ; Known history second third degree heart block ( may eligible patient currently pacemaker ) ; Sustained heart rate &lt; 50/minute preentry ECG ; Right bundle branch block + leave anterior hemiblock ( bifascicular block ) ; Patients myocardial infarction unstable angina within 6 month prior start study drug ; CHF NY Heart Association class III IV . 9 . **continued : Atrial fibrillation document within 2 week prior first dose study drug ; Patients require treatment concomitant drug prolong QT/QTc interval strong CYP3A4 inhibitor inducer exception antibiotic , antifungal , antiviral use standard care prevent treat infection drug consider absolutely essential care subject . 10 . Known family history congenital long QT syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Quizartinib</keyword>
	<keyword>AC220</keyword>
	<keyword>ASP2689</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>AZA</keyword>
	<keyword>Vidaza</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-Azacytidine</keyword>
	<keyword>5-AZA</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>MTD</keyword>
	<keyword>Overall response</keyword>
	<keyword>Complete remission</keyword>
	<keyword>CR</keyword>
	<keyword>Complete remission incomplete blood count recovery</keyword>
	<keyword>Cri</keyword>
	<keyword>Partial remission</keyword>
	<keyword>PR</keyword>
	<keyword>Hematologic improvement</keyword>
	<keyword>HI</keyword>
</DOC>